Recent Updates
Recently added Catalysts

GSK5864399

Phase 1/2

Solid Tumours | Small Molecules | Oncology |GSK plc|Trials Updated: Nov 18, 2026

GSK5864399 development status

Highest phase Phase 1/2
Registered trials 1 across 1 sponsor since Nov 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLED
Total Trials1
Total Enrollment155

FDA Designations

No designations recorded

GSK5864399 clinical trials

GSK5864399 · 1 trial · 1 indication

Phase 1/2 1
NCT07947134A Study of GSK5864399 Administered Alone or in Combination With Other Anti-cancer Agents in Participants With Solid TumoursSolid Tumours
NOT YET_RECRUITING155 Analytics
PHASE1/PHASE2NOT YET_RECRUITING
A Study of GSK5864399 Administered Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumours
Solid TumoursUnlock trial analytics

Study Endpoints

Primary Endpoints

Part 1 & 2: Number of participants with Adverse events (AEs) by National Cancer Institute-Common terminology criteria for adverse events (NCI-CTCAE) Version 6.0
Up to approximately 155 weeks
Part 1: Number of participants with Dose-Limiting Toxicities (DLTs)
Up to approximately 155 weeks
Part 1 & 2: Number of participants with changes in safety parameters
Up to approximately 155 weeks
Part 1 & 2: Number of participants with Adverse events (AEs), Serious Adverse Events (SAEs) by severity
Up to approximately 155 weeks
Part 1 & 2: Number of participants with AEs leading to dose modifications
Up to approximately 155 weeks
Part 1 & 2: Number of participants with a change from baseline in body weight
Up to approximately 155 weeks
Part 1 & 2: Number of participants with a change from baseline in laboratory parameters (hematology, clinical chemistry and urinalysis)
Up to approximately 155 weeks
Part 1 & 2: Number of participants with a change from baseline in cardiac function: Electrocardiogram (ECG)
Up to approximately 155 weeks
Part 1 & 2: Number of participants with a change from baseline in Eastern Cooperative Oncology Group (ECOG) performance status
Up to approximately 155 weeks
Part 2: Confirmed Objective Response Rate (cORR)
Up to approximately 155 weeks

cORR is defined as the proportion of participants who have achieved a Best of response (BOR) of Complete Response (CR) or Partial Response (PR) as assessed by the Investigator and confirmed by repeat assessments at least 4 weeks after the initial response is documented, according to Response Evaluation Criteria in Solid Tumours (RECIST) version (v) 1.1.

Secondary Endpoints

Part 1& 2: Maximum concentration (Cmax) of GSK5864399
Up to approximately 161 weeks
Part 1& 2: Time to maximum concentration (Tmax) of GSK5864399
Up to approximately 161 weeks
Part 1& 2: Area under the concentration-time curve (AUC) of GSK5864399
Up to approximately 161 weeks
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelSEQUENTIAL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Part 1: Dose EscalationEXPERIMENTAL -
Part 2: Dose ExpansionEXPERIMENTAL -

Interventions

NameTypeDescription
GSK5864399DRUGGSK5864399 will be administered
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo

Inclusion Criteria: Participants are eligible to be included in the study only if all of the following criteria apply: * Is at least 18 years of age or the legal age of consent. * Has histologically confirmed unresectable metastatic disease of either: * colorectal cancer that has progressed thr...

Unlock Eligibility Criteria

Competitive Landscape -Other Solid Tumors 10 trials (matched to "Solid Tumours")

Recent Changes (Last 90 Days)

LOWNov 18, 2026NCT07947134New Trial Detected: Not Yet Recruiting

Frequently asked questions about GSK5864399

What is GSK5864399 used for?

GSK5864399 is an investigational small molecule being studied for the treatment of solid tumours. It is in Phase 1/2 clinical development and is not yet available as a marketed therapy. The program is being run by GSK plc.

Who is developing GSK5864399?

GSK5864399 is being developed by GSK plc, which trades under the ticker GSK. The company is sponsoring the clinical program evaluating the compound in participants with solid tumours.

What phase is GSK5864399 in?

GSK5864399 is in Phase 1/2 clinical development. It is an investigational agent and has not completed the clinical testing required for regulatory approval. The single registered trial is currently listed as not yet recruiting.

What clinical trial is GSK5864399 being studied in?

GSK5864399 is being evaluated in trial NCT07947134, titled A Study of GSK5864399 Administered Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumours. The Phase 1/Phase 2 trial is controlled, randomized, and plans to enroll 155 participants aged 18 years and older.

Is GSK5864399 given alone or with other cancer drugs?

Trial NCT07947134 is designed to test GSK5864399 both as a single agent and in combination with other anti-cancer agents in participants with solid tumours. The study is randomized and controlled, with an planned enrollment of 155 participants.